AbCellera Biologics Inc. (ABCL) Stock Analysis
$ABCL · Healthcare · Biotechnology · NASDAQ
AbCellera Biologics (ABCL), a Biotechnology company, is listed on NASDAQ and has a market capitalization of about $3.86B.
Price
$11.91
Market cap
$3.86B
Dividend yield
—
About AbCellera Biologics Inc.
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
How StockWorthy values ABCL
StockWorthy forecasts AbCellera Biologics Inc.'s revenue, operating profitability, reinvestment (capital expenditure, depreciation and working capital) and unlevered free cash flow, then discounts those cash flows using a normalized cost of capital built from ABCL's size, profitability and balance-sheet risk. Terminal growth is adjusted to reflect the company's mature growth profile rather than a fixed number. The model presents bear, base and bull scenarios, and every key assumption stays transparent and adjustable in the full StockWorthy analysis. Results are educational and not investment advice.
Related stocks
See ABCL's Fair Value
Create a free account to view AbCellera Biologics Inc.'s base-case fair value, the bear–bull modeled range, and every assumption behind them. Free accounts include 5 stock valuations per month — plus Advanced DCF models, financial charts, dividends, and peer analysis.